GlassScriptPhysician profile
Elsaid A Balboul
NPI 1467421339
$2,323.89
in general payments reported to CMS, 2019-2025
25 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $134 · 2021: $369 · 2022: $692 · 2023: $480 · 2024: $243 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $446.66 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $306.05 | 2020-2025 | Sogroya |
| Bayer Healthcare Pharmaceuticals INC. | $245.38 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $202.28 | 2020-2025 | Xtampza |
| Pfizer INC. | $141.32 | 2019-2023 | |
| Abbvie INC. | $130.90 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $107.37 | 2020-2023 | Lokelma |
| Lilly USA, LLC | $106.12 | 2019-2023 | Trulicity |
| Neurocrine Biosciences, INC. | $104.05 | 2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $74.93 | 2019-2023 | |
| Amgen INC. | $74.69 | 2023-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $69.29 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $45.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $41.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.80 | 2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.23 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $25.73 | 2019-2021 | |
| Nevro Corp. | $24.47 | 2021 | |
| Lundbeck LLC | $19.05 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.99 | 2025 | Caplyta |
| Invivyd INC | $16.52 | 2025 | Pemgarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.96 | 2022 | |
| Sun Pharmaceutical Industries INC. | $12.90 | 2021 | |
| Eisai INC. | $12.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsaid Balboul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.